What changed today in Metabolic: 4 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
Semaglutide
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and marketed under brand names including Ozempic, Wegovy and Rybelsus for different indications.
Building
- Editorial attention
- Building
- Tracked this week
- 9
- Sources this week
- 4
- Last activity
- 3 days ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Semaglutide at a glance
- About this topic
- Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and marketed under brand names including Ozempic, Wegovy and Rybelsus for different indications.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 12, 2026)
- Key facts from tracked records
- 129 clinical trials tracked from ClinicalTrials.gov
- 25 NPHLA briefings on this topic
What’s the latest on Semaglutide?
25 totalWhat changed today in Metabolic: 13 trial updates, 2 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
What changed today in Metabolic: 5 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records11 sources1 min read
What changed today in Aesthetics & Longevity: 2 trial updates, 1 final rule, 1 new study
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
Automated from official records5 sources1 min read
What changed today in Metabolic: 4 new studies, 2 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
What changed today in Metabolic: 4 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
What changed today in Metabolic: 8 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Regulatory: 1 new study
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
What do the official records show?
Primary sources and peer-reviewed research- New trial registered: Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults (opens the source in a new tab)
Phase 1, Korea United Pharm. Inc.. Conditions: Bioequivalence; Pharmacokinetics. Interventions: Semaglutide (UI112); Semaglutide (UIC202611). Investigational: trial-stage therapies are not approved for the use studied.
- Trial status changed to “Completed”: A Study of BGM0504 in Participants With Type 2 Diabetes (opens the source in a new tab)
Phase 3, BrightGene Bio-Medical Technology Co., Ltd.. Previously “Active, not recruiting”. Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC; Drug: Semaglutide Administered SC. Investigational: tr…
- New trial registered: AMBITION 3 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body…) (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Type 2 Diabetes. Interventions: Zenagamtide; Semaglutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: AMBITION4 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared…) (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Interventions: Zenagamtide; Semaglutide; Placebo zenagamtide; Placebo semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Trial status changed to “Recruiting”: A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes (opens the source in a new tab)
Phase 2, Hoffmann-La Roche. Previously “Active, not recruiting”. Conditions: Type 2 Diabetes Mellitus. Interventions: Tifeglipron; Semaglutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial (opens the source in a new tab)
- New trial registered: Ocular Changes in Patients Using Tirzepatide or Semaglutide (opens the source in a new tab)
Istanbul University. Conditions: Type 2 Diabetes Mellitus; Obesity. Interventions: Semaglutide; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus (opens the source in a new tab)
Phase 2, Shenzhen Salubris Pharmaceuticals Co., Ltd.. Conditions: Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes; T2DM. Interventions: SAL0150 dose 1; SAL0150 dose 2; SAL0150 dose 2; SAL0150 dose 3; SAL0150 dose 3; Placebo; Semaglutide inject 1.0 mg. Investigational: trial-s…
Which clinical trials are being tracked?
All trials- Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults
Korea United Pharm. Inc.. Conditions: Bioequivalence; Pharmacokinetics. Investigational — not approved for the use studied.
- A Study of BGM0504 in Participants With Type 2 Diabetes
BrightGene Bio-Medical Technology Co., Ltd.. Conditions: Type 2 Diabetes Mellitus (T2DM). Status changed from “Active, not recruiting” on Nov 13, 2026. Investigational — not approved for the use studied.
- AMBITION 3: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Novo Nordisk A/S. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- AMBITION4: A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications
University of Virginia. Conditions: GLP-1 Receptor Agonist Treatment. Investigational — not approved for the use studied.
- COURAGE: A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals. Conditions: Obesity. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk (opens the source in a new tab)
- #AHA26: Lilly gets another sleep apnea win, this time with obesity pill (opens the source in a new tab)
- Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts (opens the source in a new tab)